Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NEA
Biotech
Novo powers transatlantic rare disease fund to $124M first close
Led by VCs who spent years at Lundbeckfonden and NEA, Sound Bioventures will back biotechs that are either in or on the cusp of the clinic.
Nick Paul Taylor
Jan 4, 2022 7:40am
Recludix emerges with $60M, Seagen exec Nancy Whiting at helm
Nov 15, 2021 8:00am
Stablix emerges from stables with cash for protein stabilization
Jun 3, 2021 8:00am
NEA-backed Allay exits stealth with clinical pain data
May 13, 2021 8:25am
Arcellx raises $85M to take anti-BCMA cell therapy into humans
Oct 4, 2019 8:28am
Nkarta nets $114M to push NK cell therapies into the clinic
Sep 4, 2019 10:05am